X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Intellectual property firm Finnegan, Henderson, Farabow, Garrett & Dunner ended 2003 with little fanfare. The firm registered a 3 percent drop in revenue in its D.C.-area offices from the year before, but a 4 percent increase firmwide. Across all offices, the D.C.-based firm had one fewer lawyer than in 2002, but increased its head count of equity partners by 6 percent, from 78 to 83. Managing partner Christopher Foley says the work was steady last year, but not in “overabundance.” He notes, however, that the firm experienced an uptick in workload in the last half of the year. Foley blames the slowdown in growth to a downturn in the market for initial public offerings and Internet-based work. He says it led to a decline in trademark work for the firm. The much-reported economic downturn that began in 2001 most affected the firm’s IP work in computers, communications, and electrical practices, Foley says. The managing partner also blamed the economic downturn on fewer research and development dollars, which led to less work in areas such as patent application filings. On the other hand, the firm’s litigation practice, 60 percent of the firm’s work, kept Finnegan lawyers busy last year. In particular, the pharmaceutical practice continued to soar, and the firm managed several high-profile cases for drug manufacturing giants GlaxoSmithKline and Eli Lilly. The firm manages a family of cases for London-based GlaxoSmithKline relating to patent disputes over the anti-depressant Paxil, one of the company’s best-selling products. The firm also represents Indianapolis-based Eli Lilly and Co. in significant litigation to protect the company’s antipsychotic drug Zyprexa against patent challenges from other companies seeking to produce generic versions. The firm also enjoyed its thriving practice in the medical device area. As in the drug industry, “people are always coming up with new devices to help the medical industry,” Foley says. The firm represents several medical device manufacturers, including Home Diagnostics Inc., maker of blood glucose monitors used by diabetics. Other clients and big players in the industry that kept the firm busy last year included the Boston Scientific Corp., manufacturer of endoscopic devices, and the Indianapolis-based $3.2 billion Guidant Corp. Finnegan’s work for these medical device companies runs the gamut: completing and filing patent applications, patent prosecution, strategic counseling, and litigation.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]

 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.